Albert Bourla on Seagen acquisition
From Pfizer CEO doubles down on 2024 guidance, talks Seagen buy · · Yahoo Finance
“I think season is the anchor platform when we announced the acquisition of Cen back in 23 early we basically make big very big bet in two things one the ADC technology and secondly a company that we felt can excel in this technology since then I feel very good for both actually way better than when we announced the ADC technology has become the hottest thing in m&a right now every company is trying to find an ADC but you know what is available is one product here our product there with siden we were able to get a whole platform of form marketed products that they're having a very strong life cycle plan 13 assets that were in different stages of the pipeline and the knowhow and technology that it was positioning the company is the best company of ADC so I I feel that there is an overall consensus in the market that the bet on that technology was the right one now coming to the company I feel even better because since we announced the acquisition Cen was able to release data that were transformational in terms of efficacy that they were able to demonstrate in very difficult to treat cancers like blood cancer so both company and and technology is where I think we are placing our bets and I think that will be a significant anchor for us”
On , Albert Bourla, Chairman of the Board & Chief Executive Officer at Pfizer Inc, spoke about Seagen acquisition during Pfizer CEO doubles down on 2024 guidance, talks Seagen buy on Yahoo Finance.
About Albert Bourla
Albert Bourla, chairman and CEO of Pfizer, said on the company’s first-quarter 2026 earnings call that the company’s strong performance reflected “disciplined execution” and that new and acquired products grew 22% in the quarter. He stated that Pfizer does not plan a large merger in the near term, describing the next few years as a time to “execute on AI transformation” rather than pursue a mega-merger. Bourla also highlighted recent patent settlements for Vyndamax, which he said give the company confidence it will enter a period of high single-digit revenue growth starting in 2029. He noted that Pfizer invested nearly $80 billion in recent years to acquire molecules and pipelines to offset upcoming patent losses. In multiple interviews, Bourla discussed the rise of China’s pharmaceutical sector, arguing that the U.S. should focus on improving its own innovation rather than trying to slow China’s progress. He described China’s scientific capabilities as having a “meteoric rise” and said that by the end of the decade, eight of the world’s top ten universities based on peer-reviewed publications were Chinese. Bourla expressed optimism about artificial intelligence, calling it “transformative” and predicting it will contribute to a “scientific renaissance” in medicine. He also commented on U.S. health policy, saying he was encouraged by recent statements from Trump administration officials about modernizing the FDA and accelerating drug development, though he said he had not yet seen practical effects. Bourla described his increased time in Washington as necessary because health care has become “extremely politicized” and because governments are major customers for Pfizer.